-
Mashup Score: 0
Steven Pipe, MD, at the University of Michigan, discusses the long-term results from the phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational gene therapy for hemophilia B.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Steven Pipe, MD, at the University of Michigan, discusses the long-term results from the phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational gene therapy for hemophilia B.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Steven Pipe, MD, at the University of Michigan, discusses the long-term results from the phase 3 HOPE-B trial evaluating etranacogene dezaparvovec #EtranaDez, an investigational gene therapy for hemophilia B. @UMich @NHF_Hemophilia @HemoFoundation https://t.co/womtQcrqbw https://t.co/A865OLYzS8
-
-
Mashup Score: 1
Steven Pipe, MD, at the University of Michigan, discusses the long-term results from the phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational gene therapy for hemophilia B.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Steven Pipe, MD, at the University of Michigan, discusses the long-term results from the phase 3 HOPE-B trial evaluating etranacogene dezaparvovec #EtranaDez, an investigational gene therapy for hemophilia B. @UMich @NHF_Hemophilia @HemoFoundation https://t.co/womtQcrqbw https://t.co/rqb4y4pIEU
-
-
Mashup Score: 2
Steven Pipe, MD, at the University of Michigan, discusses the long-term results from the phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational gene therapy for hemophilia B.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Steven Pipe, MD, at the University of Michigan, discusses the long-term results from the phase 3 HOPE-B trial evaluating etranacogene dezaparvovec #EtranaDez, an investigational gene therapy for hemophilia B. @UMich @NHF_Hemophilia @HemoFoundation https://t.co/womtQcrqbw https://t.co/ygUEckcfmp
-
-
Mashup Score: 0
Steven Pipe, MD, at the University of Michigan, discusses the long-term results from the phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational gene therapy for hemophilia B.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Steven Pipe, MD, at the University of Michigan, discusses the long-term results from the phase 3 HOPE-B trial evaluating etranacogene dezaparvovec #EtranaDez, an investigational gene therapy for hemophilia B. @UMich @NHF_Hemophilia @HemoFoundation https://t.co/womtQcrqbw https://t.co/fQRBGXdC9H
-
-
Mashup Score: 1
Steven Pipe, MD, at the University of Michigan, discusses the long-term results from the phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational gene therapy for hemophilia B.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Steven Pipe, MD, at the University of Michigan, discusses the long-term results from the phase 3 HOPE-B trial evaluating etranacogene dezaparvovec #EtranaDez, an investigational gene therapy for hemophilia B. @UMich @NHF_Hemophilia @HemoFoundation https://t.co/womtQcrqbw https://t.co/tk7RTrguwD
-
Steven Pipe, MD, at the University of Michigan, discusses the long-term results from the phase 3 HOPE-B trial evaluating etranacogene dezaparvovec #EtranaDez, an investigational gene therapy for hemophilia B. @UMich @NHF_Hemophilia @HemoFoundation https://t.co/womtQcrqbw https://t.co/xfxmlQAOWp